SynthesisRheumatology (Oxford, England)2021
A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies.
Synthesis in Rheumatology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 72 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- Integrating Machine Learning into Myositis Research: a Systematic Review.Clinical reviews in allergy & immunology · 2025Pooled it
- International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative.Nature reviews. Rheumatology · 2023Guideline
- Cancer-associated myositis: a single-centre 20-year experience.Clinical rheumatology · 2026Article
- Different age, different phenotype: a comparative analysis of juvenile and adult-onset dermatomyositis from a tertiary centre.Rheumatology (Oxford, England) · 2026Article
- Clinicopathological and serological spectrum of idiopathic inflammatory myopathies: Experience from a neuromuscular referral center in Cyprus.Journal of neuromuscular diseases · 2026Article
- Article
- Article
- Epidemiology of idiopathic inflammatory myopathies: a population-based cohort in England, 2002-2021.RMD open · 2026Article
- Pancreatic Adenocarcinoma Presented as Paraneoplastic Dermatomyositis Complicated with Rhabdomyolysis: Case Report and Review.The American journal of case reports · 2026Review
- Article
- Using B-cell-targeting drugs to achieve marked efficacy in anti-signal recognition particle myopathy: two case reports.Immunologic research · 2026Article
- Dermatomyositis: Prevalence, Clinical Spectrum, Diagnostic Approach, and Management Strategies.Archives of internal medicine research · 2026Article
- Malignancy in anti-synthetase syndrome: clinical features and prognostic impact from a multicenter retrospective study.Frontiers in medicine · 2026Article
- Clinical Characteristics and Malignancy Prevalence in Idiopathic Inflammatory Myopathies: A Single-Center Study from Southwestern Saudi Arabia.Open access rheumatology : research and reviews · 2026Article
- A five-factor risk-stratification model for cancer-associated myositis in idiopathic inflammatory myopathies and stage-specific survival analysis: a multicentre Japanese MYKO cohort study.Frontiers in immunology · 2026Article
- Prognostic Implications of Myositis-Specific Autoantibodies on Mortality, Relapse, and Remission in Dermatomyositis Patients.European journal of neurology · 2025Article
- Shared molecular profiles of anti-PL12 autoantibodies in anti-synthetase syndrome.Rheumatology (Oxford, England) · 2025Article
- Revisiting the link between oropharyngeal dysphagia and cancer in autoimmune myositis: a descriptive study.Arthritis research & therapy · 2025Article
- The SCRIM score: a clinical tool for cancer risk-stratification in patients with idiopathic inflammatory myopathy.Arthritis research & therapy · 2025Article
- Malignancy Risk and Predictors in Dermatomyositis and Polymyositis: A Large Population-Based Study.Medicina (Kaunas, Lithuania) · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
19 authors at 16 institutions in 4 countries.
Funding
Abstract
objectivesTo identify clinical factors associated with cancer risk in the idiopathic inflammatory myopathies (IIMs) and to systematically review the existing evidence related to cancer screening.
methodsA systematic literature search was carried out on Medline, Embase and Scopus. Cancer risk within the IIM population (i.e. not compared with the general population) was expressed as risk ratios (RR) for binary variables and weighted mean differences (WMD) for continuous variables. Evidence relating to cancer screening practices in the IIMs were synthesized via narrative review.
resultsSixty-nine studies were included in the meta-analysis. DM subtype (RR 2.21), older age (WMD 11.19), male sex (RR 1.53), dysphagia (RR 2.09), cutaneous ulceration (RR 2.73) and anti-transcriptional intermediary factor-1 gamma positivity (RR 4.66) were identified as being associated with significantly increased risk of cancer. PM (RR 0.49) and clinically amyopathic DM (RR 0.44) subtypes, Raynaud's phenomenon (RR 0.61), interstitial lung disease (RR 0.49), very high serum creatine kinase (WMD -1189.96) or lactate dehydrogenase (WMD -336.52) levels, and anti-Jo1 (RR 0.45) or anti-EJ (RR 0.17) positivity were identified as being associated with significantly reduced risk of cancer. Nine studies relating to IIM-specific cancer screening were included. CT scanning of the thorax, abdomen and pelvis appeared to be effective in identifying underlying asymptomatic cancers.
conclusionCancer risk factors should be evaluated in patients with IIM for risk stratification. Screening evidence is limited but CT scanning could be useful. Prospective studies and consensus guidelines are needed to establish cancer screening strategies in IIM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.